AGI-101H / National Cancer Institute - LARVOL DELTA

Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization. (PubMed, Cancers (Basel)) - "Third, we show that immunization with MA restored natural CD8+ T cell autoimmunity to MA in 85% of the MM patients. The role of natural T cell autoimmunity to tumor-associated MA is discussed based on discrete levels of T cell activation thresholds."

Journal • Immunology • Melanoma • Oncology • Solid Tumor • IFNG • Tyrosinase

BNIP3L Is a New Autophagy Related Prognostic Biomarker for Melanoma Patients Treated With AGI-101H. (PubMed, Anticancer Res) - "BNIP3L is a candidate prognostic marker of clinical outcome of melanoma patients treated with AGI-101H, and may be considered as a prediction marker for patient survival."

Biomarker • Clinical • Journal • Melanoma • Oncology • Solid Tumor

The transcriptomic profile of peripheral T cells that maintain dormant state of melanoma cells in patients treated with allogenic melanoma vaccine (CRI-CIMT-EATI-AACR 2018) - "Among these 538 markers, the expression of 14 (with;log2FC| > 1) is now being validated with RT-qPCR and FACS. Also, GSEA analysis revealed significant enrichment of “TNFa_signaling_via_NFkB”, “TGFb_signaling” and “G2/M_checkpoint” hallmark processes (MSigDB Hallmark gene sets) in AGI-101H vaccinated patients, that indicates considerable activation of anti-tumor response and prevention of conversion of MM dormant cells into proliferative metastases.Transcriptome profiling of peripheral T cells in long-surviving MM patients immunized with AGI-101H suggest activation of the molecular mechanism that sustains MM cells in the non-actively proliferative dormant state.​ "

Clinical • IO Biomarker • Melanoma • Oncology • Solid Tumor

Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6. (PubMed, Oncoimmunology) - "In the present study, high levels of BCL6 transcripts negatively correlated with the expression of several exhaustion markers (CTLA4, KLRG1, PTGER2, IKZF2, TIGIT). Therefore, Bcl6 seems to promote a progenitor fate for cancer-experienced T cells from AGI-101H-vaccinated patients by repressing the exhaustion markers."

Cancer stem cells • IO Biomarker • Journal • BCL6 • IL2 • STAT5

Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results. (PubMed, J Immunother Cancer) - "Vaccination beyond recurrence of the disease with additional re-induction combined with surgery or alone increased long term survival of melanoma patients. However, further studies on larger patient cohorts are required."

Clinical • Journal